Our patient, who harbored both EGFR and somatic BRCA2 mutations, demonstrated a durable response to Olaparib lasting approximately 21 months, representing the longest reported duration of response to Olaparib in NSCLC with LM to date. Here, BRCA2 is linked to non-small cell lung carcinoma.